ES2539917T3 - GLP-2 para su uso en el tratamiento de la atrofia muscular - Google Patents
GLP-2 para su uso en el tratamiento de la atrofia muscular Download PDFInfo
- Publication number
- ES2539917T3 ES2539917T3 ES10762684.8T ES10762684T ES2539917T3 ES 2539917 T3 ES2539917 T3 ES 2539917T3 ES 10762684 T ES10762684 T ES 10762684T ES 2539917 T3 ES2539917 T3 ES 2539917T3
- Authority
- ES
- Spain
- Prior art keywords
- glp
- treatment
- rats
- activities
- jejunum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract description 22
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract description 22
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract description 22
- 201000000585 muscular atrophy Diseases 0.000 title 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 abstract description 2
- 230000025185 skeletal muscle atrophy Effects 0.000 abstract description 2
- 101710173664 Glucagon-2 Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 235000003642 hunger Nutrition 0.000 description 14
- 210000001630 jejunum Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003405 ileum Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 5
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000037351 starvation Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102100037469 Protein DEPP1 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172398 | 2009-10-07 | ||
| EP09172398A EP2311486A1 (en) | 2009-10-07 | 2009-10-07 | GLP-2 for use in intestine and muscle recovery |
| PCT/EP2010/065021 WO2011042501A2 (en) | 2009-10-07 | 2010-10-07 | The intestine and muscle recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2539917T3 true ES2539917T3 (es) | 2015-07-07 |
Family
ID=41611235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10762684.8T Active ES2539917T3 (es) | 2009-10-07 | 2010-10-07 | GLP-2 para su uso en el tratamiento de la atrofia muscular |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120270786A1 (enExample) |
| EP (2) | EP2311486A1 (enExample) |
| JP (1) | JP5801814B2 (enExample) |
| CN (1) | CN102711803B (enExample) |
| AU (1) | AU2010305420B2 (enExample) |
| BR (1) | BR112012009380A2 (enExample) |
| CA (1) | CA2776964C (enExample) |
| DK (1) | DK2485756T3 (enExample) |
| ES (1) | ES2539917T3 (enExample) |
| IN (1) | IN2012DN03187A (enExample) |
| WO (1) | WO2011042501A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2909211C (en) * | 2013-04-15 | 2021-06-22 | Nestec S.A. | Use of whey protein in combination with electrical muscle stimulation |
| JP6325215B2 (ja) * | 2013-08-29 | 2018-05-16 | テルモ株式会社 | 栄養補給用冷菓 |
| WO2016058919A1 (en) * | 2014-10-14 | 2016-04-21 | Nestec S.A. | Improvement in muscle functionality of elderly males |
| US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| KR101661332B1 (ko) * | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
| KR102119188B1 (ko) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
| US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| EP0906338B1 (en) * | 1996-04-12 | 2002-11-06 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
| WO2002022151A2 (en) * | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| ATE396202T1 (de) * | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| EP1554308A2 (en) * | 2002-10-14 | 2005-07-20 | Novo Nordisk A/S | Glucagon-like peptide - 2 variants |
| US20040115708A1 (en) * | 2002-10-28 | 2004-06-17 | Ardies C. Murray | Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia |
| CN1822851B (zh) * | 2003-05-15 | 2011-04-13 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
| DK1868454T3 (da) * | 2005-04-06 | 2013-04-02 | Nestec Sa | Sammensætning til ernæringsmæssig forbedring af glucosekontrol og insulinvirkning |
| CN101365350A (zh) * | 2006-01-09 | 2009-02-11 | 雀巢技术公司 | 应激患者的治疗 |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
-
2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
-
2010
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/pt not_active Application Discontinuation
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/zh active Active
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/ja active Active
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en not_active Ceased
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305420A1 (en) | 2012-05-10 |
| EP2311486A1 (en) | 2011-04-20 |
| JP2013507341A (ja) | 2013-03-04 |
| CN102711803B (zh) | 2017-02-22 |
| CN102711803A (zh) | 2012-10-03 |
| WO2011042501A3 (en) | 2011-06-03 |
| EP2485756B1 (en) | 2015-05-20 |
| CA2776964C (en) | 2019-03-05 |
| US20120270786A1 (en) | 2012-10-25 |
| IN2012DN03187A (enExample) | 2015-09-25 |
| BR112012009380A2 (pt) | 2021-06-22 |
| JP5801814B2 (ja) | 2015-10-28 |
| CA2776964A1 (en) | 2011-04-14 |
| WO2011042501A2 (en) | 2011-04-14 |
| DK2485756T3 (en) | 2015-06-08 |
| EP2485756A2 (en) | 2012-08-15 |
| HK1173949A1 (en) | 2013-05-31 |
| AU2010305420B2 (en) | 2015-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| PE20050123A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas y composiciones farmaceuticas que los incluyen | |
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| NO20060329L (no) | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse | |
| BRPI0412761A (pt) | inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| TW200505423A (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| AR037081A1 (es) | Composicion para el suministro transdermico de fentanilo | |
| PE20040157A1 (es) | Progestinas no esteroides | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| WO2002078627A3 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| RU2004132833A (ru) | Лекарственные формы, полезные для лечения мужской и женской импотенции | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| AR047776A1 (es) | Composiciones farmaceuticas glp - 1 | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| MX347237B (es) | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| BRPI0517391A (pt) | forma de dosagem com lapso de tempo de medicamentos para a terapia de insÈnia | |
| HUP0301828A2 (hu) | Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására | |
| MXPA06007510A (es) | Composiciones de farmaco y formas de dosis novedosas de topiramato. | |
| RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
| PE20061314A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis |